加载中
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
前收盘价
US$1.22
−US$0.005 · -0.41%
盘后
US$1.2269
+US$0.0069 · +0.57%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
日内区间
当前US$1.22
52周区间
当前US$1.22
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
81
深度低估
情绪
50
多空交织
风险
47
风险偏高
动量
54
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
日内区间
当前US$1.22
52周区间
当前US$1.22
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.84亿 USD | 7699.4万 USD | 23.7万 USD | 59.6万 USD | 139.3万 USD |
| 销货成本 | 474.5万 USD | 125.6万 USD | — | — | — |
| 毛利 | 1.79亿 USD | 7573.8万 USD | 23.7万 USD | 59.6万 USD | 139.3万 USD |
| 研究与开发 | 7371.5万 USD | 1.04亿 USD | 1.25亿 USD | 9551.8万 USD | 8572.7万 USD |
| 销售、一般及管理费用 | 1.59亿 USD | 1.46亿 USD | 6913.5万 USD | 4362.8万 USD | 2966.5万 USD |
| 营业费用 | 2.33亿 USD | 2.49亿 USD | 1.94亿 USD | 1.39亿 USD | 1.15亿 USD |
| 利息收入 | 1811.7万 USD | 1960.7万 USD | 1815.2万 USD | 252.9万 USD | 52.7万 USD |
| 利息支出 | 3265.7万 USD | 1850.4万 USD | 831.2万 USD | 688.2万 USD | 374万 USD |
| 折旧和摊销 | 120.4万 USD | 122.1万 USD | 103.3万 USD | 86.8万 USD | 78.3万 USD |
| 营业利润 | −5383.5万 USD | −1.74亿 USD | −1.94亿 USD | −1.39亿 USD | −1.14亿 USD |
| 净利润 | −8578.2万 USD | −1.75亿 USD | −1.84亿 USD | −1.42亿 USD | −1.16亿 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$5.89
上涨空间 382.79%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2014年7月22日 | 529:500 | — | — |
已生效 2014年7月22日
529:500
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3046.94万0.00%2.3万亿 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI2177.66万0.22%103.03亿 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM1773.25万0.02%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF929.54万0.01%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO639.22万0.05%139.17亿 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB604.39万0.06%108.2亿 USD0.44%US$204.26-1.08%
Vanguard Russell 2000 ETFVTWO479.08万0.03%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA376.58万0.02%218.24亿 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
